ADVM Adverum Biotechnologies, Inc.

2.70
0  -2%
Previous Close 2.75
Open 2.75
Price To book 0.53
Market Cap 113.57M
Shares 42,063,000
Volume 182,533
Short Ratio 2.08
Av. Daily Volume 209,985

SEC filingsSee all SEC filings

  1. 8-K - Current report 17701508
  2. 8-K - Current report 17688782
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17676448
  4. 8-K - Current report 17666602
  5. 8-K - Current report 17654724

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  2. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events
  3. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  4. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
  5. Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors
  6. ADVERUM BIOTECHNOLOGIES, INC. Financials
  7. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 10-K, Annual Report
  8. Adverum Biotechnologies posts 4Q loss
  9. Adverum Biotechnologies posts 4Q loss
  10. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  11. Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update
  12. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  13. Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
  14. Adverum Biotechnologies to Present at Upcoming Investor Conferences
  15. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  16. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
  17. ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  18. Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
  19. Is KCAP Financial Inc (KCAP) A Good Stock to Buy?
  20. Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy?